The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

"Novartis’ mAb could become first Sjögren’s disease drug after Phase III success" was originally created and published by ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

Patients with Sjögren syndrome have an increased risk for non-Hodgkin lymphoma. It is estimated that approximately 10% of patients with significant dry eye disease have Sjögren syndrome.

Considering that IgG4-related syndrome also affects the parotid glands frequently, this overlap in symptoms further supports biopsy as a method to ensure the correct diagnosis of Sjögren's ...